trial

A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

NCTId NCT00737256
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 44 (estimated)
Sponsored by Paul Saenger
Primary completion 2013-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
44 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-08
Primary completion
2013-05
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AripiprazolePerphenazine

Sponsors

Paul SaengerLead Sponsor

Investigators

1
Thomas P Beresford, MDPrincipal Investigator

Sites

1 total
Denver, United States

Linked catalysts

1
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and — primary completion2013-05

Facts & assertions

4 sourced
Enrollment
44
Phase
PHASE2
Primary Completion Date
2013-05
Status
UNKNOWN
relationships
The graph out of here
drug
Aripiprazole
drug
Perphenazine
drug
lead_sponsor
Paul Saenger
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cocaine Dependence
indication
investigator
Thomas P Beresford, MD
person